Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;25(2):131-139.
doi: 10.1089/dia.2022.0340. Epub 2022 Nov 29.

A Longitudinal View of Disparities in Insulin Pump Use Among Youth with Type 1 Diabetes: The SEARCH for Diabetes in Youth Study

Affiliations

A Longitudinal View of Disparities in Insulin Pump Use Among Youth with Type 1 Diabetes: The SEARCH for Diabetes in Youth Study

Estelle M Everett et al. Diabetes Technol Ther. 2023 Feb.

Abstract

Objective: To evaluate changes in insulin pump use over two decades in a national U.S. sample. Research Design and Methods: We used data from the SEARCH for Diabetes in Youth study to perform a serial cross-sectional analysis to evaluate changes in insulin pump use in participants <20 years old with type 1 diabetes by race/ethnicity and markers of socioeconomic status across four time periods between 2001 and 2019. Multivariable generalized estimating equations were used to assess insulin pump use. Temporal changes by subgroup were assessed through interactions. Results: Insulin pump use increased from 31.7% to 58.8%, but the disparities seen in pump use persisted and were unchanged across subgroups over time. Odds ratio for insulin pump use in Hispanic (0.57, confidence interval [95% CI] 0.45-0.73), Black (0.28, 95% CI 0.22-0.37), and Other race (0.49, 95% CI 0.32-0.76) participants were significantly lower than White participants. Those with ≤high school degree (0.39, 95% CI 0.31-0.47) and some college (0.68, 95% CI 0.58-0.79) had lower use compared to those with ≥bachelor's degree. Those with public insurance (0.84, 95% CI 0.70-1.00) had lower use than those with private insurance. Those with an annual household income <$25K (0.43, 95% CI 0.35-0.53), $25K-$49K (0.52, 95% CI 0.43-0.63), and $50K-$74K (0.79, 95% CI 0.66-0.94) had lower use compared to those with income ≥$75,000. Conclusion: Over the past two decades, there was no improvement in the racial, ethnic, and socioeconomic inequities in insulin pump use, despite an overall increase in use. Studies that evaluate barriers or test interventions to improve technology access are needed to address these persistent inequities.

Keywords: Diabetes disparities; Insulin pump; Insurance coverage; Socioeconomic status; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

No competing financial interests exist.

Figures

FIG. 1.
FIG. 1.
Adjusted predicted marginal probabilities and odds ratio for pump use over time by our subgroups of interest. (a) Race/ethnicity, (b) Parental Education, (c) Household Income and (d) Health Insurance. Figures show adjusted marginal prevalence (column graph) and adjusted odds ratio (table) for insulin pump use by patient characteristics and year. *p-Value for statistically significant differences in prevalence for pump use between period 1 (2001–2005) and period 4 (2016–2019) is noted in the table.
FIG. 1.
FIG. 1.
Adjusted predicted marginal probabilities and odds ratio for pump use over time by our subgroups of interest. (a) Race/ethnicity, (b) Parental Education, (c) Household Income and (d) Health Insurance. Figures show adjusted marginal prevalence (column graph) and adjusted odds ratio (table) for insulin pump use by patient characteristics and year. *p-Value for statistically significant differences in prevalence for pump use between period 1 (2001–2005) and period 4 (2016–2019) is noted in the table.

References

    1. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363(4):311–320; doi: 10.1056/NEJMoa1002853 - DOI - PubMed
    1. Rubin RR, Peyrot M; STAR 3 Study Group. Health-related quality of life and treatment satisfaction in the sensor-augmented pump therapy for A1C reduction 3 (STAR 3) trial. Diabetes Technol Ther 2012;14(2):143–151; doi: 10.1089/dia.2011.0162 - DOI - PMC - PubMed
    1. Polonsky WH, Hessler D, Layne JE, et al. Impact of the Omnipod® insulin management system on quality of life: A survey of current users. Diabetes Technol Ther 2016;18(10):664–670; doi: 10.1089/dia.2016.0239 - DOI - PubMed
    1. Mueller-Godeffroy E, Vonthein R, Ludwig-Seibold C, et al. Psychosocial benefits of insulin pump therapy in children with diabetes type 1 and their families: The Pumpkin Multicenter Randomized Controlled Trial. Pediatr Diabetes 2018;19(8):1471–1480; doi: 10.1111/pedi.12777 - DOI - PubMed
    1. Sheikh K, Bartz SK, Lyons SK, et al. Diabetes device use and glycemic control among youth with type 1 diabetes: A single-center, cross-sectional study. J Diabetes Res 2018;2018(5162162):1–6; doi: 10.1155/2018/5162162 - DOI - PMC - PubMed

Publication types